Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by King Wealth Management Group

King Wealth Management Group raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 84.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,750 shares of the medical equipment provider’s stock after acquiring an additional 6,750 shares during the period. King Wealth Management Group’s holdings in Hologic were worth $1,063,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of HOLX. Commonwealth Equity Services LLC grew its holdings in shares of Hologic by 1.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 61,958 shares of the medical equipment provider’s stock valued at $4,467,000 after purchasing an additional 735 shares during the period. PGGM Investments lifted its holdings in Hologic by 2.3% in the fourth quarter. PGGM Investments now owns 93,417 shares of the medical equipment provider’s stock valued at $6,734,000 after acquiring an additional 2,074 shares during the last quarter. Achmea Investment Management B.V. increased its stake in Hologic by 6.6% during the fourth quarter. Achmea Investment Management B.V. now owns 36,197 shares of the medical equipment provider’s stock worth $2,609,000 after acquiring an additional 2,252 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Finally, Sequoia Financial Advisors LLC grew its holdings in shares of Hologic by 14.6% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,468 shares of the medical equipment provider’s stock worth $610,000 after purchasing an additional 1,080 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of recent analyst reports. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Wolfe Research started coverage on Hologic in a research note on Friday, December 13th. They set a “peer perform” rating on the stock. Finally, Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research report on Monday, February 3rd. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Down 0.7 %

Shares of NASDAQ HOLX opened at $60.70 on Friday. Hologic, Inc. has a 1 year low of $60.33 and a 1 year high of $84.67. The company has a market capitalization of $13.62 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The business has a 50-day moving average of $67.65 and a two-hundred day moving average of $74.94.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.